Melbourne-based biotechnology company AdAlta (ASX:1AD) reports it has been granted a second patent for its novel therapeutics product AD-214 in Japan.
The company states the Japanese Patent Office granted Patent Number 2020-121974 entitled ‘CXCR4 binding molecules’, and it expires on 8 January 2036.
Furthermore, AdAlta states the patent is directed to polypeptides containing the binding loops of the company’s i-body AD-214 and variants related to AD-214 for treating CXCR4-related diseases and disorders. These conditions include idiopathic pulmonary fibrosis, cancer, viral infections, inflammatory diseases, sclerosis, kidney disease, eye disorders, as well as immune deficiencies, disorders and wounds.
“This patent is a valuable, additional piece of intellectual property which enables expansion of protected claims for AD-214 in Japan”
Commenting on the patent, AdAlta Chief Executive Officer (CEO) and Managing Director Tim Oldham said: “Japan is the third largest pharmaceutical market in the world and remains important to our partnering and commercialisation strategy.
This patent is a valuable, additional piece of intellectual property which enables expansion of protected claims for AD-214 in Japan, a major market for fibrosis-related diseases.”
AdAlta reports this is the second patent granted in Japan for AD-214, adding to existing patent protection. The company also notes patents for the asset exist in the US, Europe, China, Australia, India, Hong Kong and Singapore.
AdAlta is a Melbourne-based clinical stage biotechnology and drug development company focused on its proprietary i-body technology platform to solve ‘challenging’ drug targeting problems and generate a new class of single domain antibody protein therapeutics with the potential to treat some of the most ‘difficult’ medical conditions.
The i-body technology mimics the shape and stability of a ‘unique’ and ‘versatile’ antigen binding domain that was initially discovered in sharks, and then developed as a human protein. The company states the results of this technology is a range of proteins capable of interacting with ‘highly’ selective, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases.
AdAlta notes i-body is the first fully human single domain antibody scaffold, and the first based on the shark motif to reach clinical trials. In addition, the company is entering collaborative partnerships to advance the development of the i-body platform with South Australia-based Carina Biotech, and US-based GE HealthCare to fight cancer.